{
    "root": "dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Morphine Sulfate",
    "value": "20250312",
    "ingredients": [
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "MORPHINE SULFATE",
            "code": "X3P646A2J0"
        }
    ],
    "indications": "morphine sulfate injection indicated management pain severe enough require opioid analgesic alternative treatments inadequate . limitations risks addiction , abuse , misuse opioids , occur duration [ ( 5.1 ) ] , reserve morphine sulfate injection patients alternative treatment options ( e.g . , non-opioid analgesics opioid combination products ) : \u2022have tolerated expected tolerated , \u2022have provided adequate analgesia expected provide adequate analgesia morphine sulfate injection used extended period time unless pain remains severe enough require opioid analgesic alternative treatment options continue inadequate .",
    "contraindications": "\u2022 morphine sulfate injection prescribed healthcare professionals knowledgeable opioids mitigate associated risks . ( 2.1 ) \u2022 lowest effective shortest duration time consistent individual patient treatment goals . reserve titration higher doses morphine sulfate injection patients lower doses insufficiently effective expected benefits using higher dose opioid clearly outweigh substantial risks . ( 2.1 , 5 ) \u2022 many acute pain conditions ( e.g . , pain occurs number surgical procedures acute musculoskeletal injuries ) require days opioid analgesic . guidelines opioid prescribing acute pain conditions available . ( 2.1 ) \u2022 initiate dosing regimen patient individually , taking account patient \u2019 underlying cause severity pain , prior analgesic treatment response , risk factors addiction , abuse , misuse . ( 2.1 , 5.1 ) \u2022 respiratory depression occur time opioid therapy , especially initiating following increases morphine sulfate injection . consider risk selecting initial dose making dose adjustments . ( 2.1 , 5.2 ) \u2022 direct intravenous injection : initiate treatment 0.1 mg 0.2 mg per kg every 4 hours needed manage pain . ( 2.2 ) \u2022 intramuscular injection : initiate treatment 10 mg , every 4 hours needed manage pain ( based 70 kg adult ) . ( 2.2 ) \u2022 abruptly discontinue morphine sulfate injection physically-dependent patient . ( 2.4 )",
    "warningsAndPrecautions": "morphine sulfate injection , usp supplied sterile solution single dose vials intravenous ( iv ) intramuscular ( im ) follows : product code unit sale strength 475201 ndc 63323-452-01 unit 25 2 mg per ml ndc 63323-452-00 1 ml single dose vial 475401 ndc 63323-454-01 unit 25 4 mg per ml ndc 63323-454-00 1 ml single dose vial 475101 ndc 63323-451-01 unit 25 10 mg per ml ndc 63323-451-00 1 ml single dose vial store : 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] . protect light ( keep outer carton ) . discard unused portion . keep freezing . autoclave . contains preservative antioxidant . container closure made natural rubber latex .",
    "adverseReactions": "morphine sulfate injection contraindicated patients : \u2022significant respiratory depression [ ( 5.2 ) ] \u2022acute severe bronchial asthma unmonitored setting absence resuscitative equipment [ ( 5.7 ) ] \u2022concurrent monoamine oxidase inhibitors ( maois ) maois within last 14 days [ ( 5.8 ) ] \u2022known suspected gastrointestinal obstruction , including paralytic ileus [ ( 5.12 ) ] \u2022hypersensitivity morphine ( e.g . , anaphylaxis ) [ ( 6 ) ]",
    "indications_original": "Morphine Sulfate Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.\n                  \n                     \n                        Limitations of Use\n                     \n                  \n                  \n                     Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions (5.1)], reserve Morphine Sulfate Injection for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products):\n                  \n                  \n                     \n                        \u2022Have not been tolerated or are not expected to be tolerated,\n                     \n                        \u2022Have not provided adequate analgesia or are not expected to provide adequate analgesia\n                  \n                  \n                     Morphine Sulfate Injection should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.",
    "contraindications_original": "\u2022 Morphine Sulfate Injection should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks. ( 2.1 ) \u2022 Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals. Reserve titration to higher doses of Morphine Sulfate Injection for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks. ( 2.1 , 5 ) \u2022 Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available. ( 2.1 ) \u2022 Initiate the dosing regimen for each patient individually, taking into account the patient\u2019s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse. ( 2.1 , 5.1 ) \u2022 Respiratory depression can occur at any time during opioid therapy, especially when initiating the following dosage increases with Morphine Sulfate Injection. Consider this risk when selecting an initial dose and when making dose adjustments. ( 2.1 , 5.2 ) \u2022 Direct Intravenous Injection : Initiate treatment with 0.1 mg to 0.2 mg per kg every 4 hours as needed to manage pain. ( 2.2 ) \u2022 Intramuscular Injection : Initiate treatment with 10 mg, every 4 hours as needed to manage pain (based on a 70 kg adult). ( 2.2 ) \u2022 Do not abruptly discontinue Morphine Sulfate Injection in a physically-dependent patient. ( 2.4 )",
    "warningsAndPrecautions_original": "Morphine Sulfate Injection, USP is supplied as a sterile solution in single dose vials for intravenous (IV) or intramuscular (IM) use as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Product Code\n                              \n                           \n                           \n                              \n                                 Unit of Sale\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                           \n                              \n                                 Each\n                              \n                           \n                        \n                        \n                           \n                              475201\n                           \n                           \n                              NDC 63323-452-01 Unit of 25 \n                           \n                           \n                              2 mg per mL\n                           \n                           \n                              NDC 63323-452-00 \n                              1 mL Single Dose Vial \n                           \n                        \n                        \n                           \n                              475401\n                           \n                           \n                              NDC 63323-454-01 Unit of 25 \n                           \n                           \n                              4 mg per mL\n                           \n                           \n                              NDC 63323-454-00 \n                              1 mL Single Dose Vial \n                           \n                        \n                        \n                           \n                              475101\n                           \n                           \n                              NDC 63323-451-01 Unit of 25\n                           \n                           \n                              10 mg per mL\n                           \n                           \n                              NDC 63323-451-00\n                              1 mL Single Dose Vial \n                           \n                        \n                     \n                  \n                  \n                     STORE AT: 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [see USP Controlled Room Temperature].\n                  Protect from light (keep in outer carton). Discard unused portion. Keep from freezing.\n                  Do not autoclave. Contains no preservative or antioxidant.\n                  The container closure is not made with natural rubber latex.",
    "adverseReactions_original": "Morphine Sulfate Injection is contraindicated in patients with: \n                  \n                     \n                        \u2022Significant respiratory depression [see Warnings and Precautions (5.2)]\n                     \n                     \n                        \u2022Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.7)]\n                     \n                     \n                        \u2022Concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days [see Warnings and Precautions (5.8)]\n                     \n                     \n                        \u2022Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.12)]\n                     \n                     \n                        \u2022Hypersensitivity to morphine (e.g., anaphylaxis) [see Adverse Reactions (6)]"
}